<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00264212</url>
  </required_header>
  <id_info>
    <org_study_id>R_8791</org_study_id>
    <nct_id>NCT00264212</nct_id>
  </id_info>
  <brief_title>AMISH : Aprovel for Management of Isolated Systolic Hypertension</brief_title>
  <official_title>A Multicentre Prospective Randomized Open-Label 12-Week Study With Blinded Evaluation Comparing the Efficacy and Safety of Irbesartan and Irbesartan-Hydrochlorothiazide Fixed Combination With Amlodipine and Amlodipine Plus Hydrochlorothiazide in Elderly Patients With Isolated Systolic Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To compare the antihypertensive efficacy and tolerability of irbesartan and&#xD;
      irbesartan-hydrochlorothiazide fixed combination therapy with amlodipine and amlodipine plus&#xD;
      hydrochlorothiazide in the treatment of isolated systolic hypertension.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in office seated SBP at week 12</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>At 4, 8 and 12 weeks: Number of responders and normalized, Change from baseline in pulse pressure (SBP-DBP), Change from baseline in standing SBP, Safety : Change in standing SBP/DBP, incidence of orthostatic hypotension, adverse events</measure>
  </secondary_outcome>
  <enrollment>436</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irbesartan and irbesartan-hydrochlorothiazide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main criteria are listed hereafter:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  at Screening&#xD;
&#xD;
               -  Outpatients&#xD;
&#xD;
               -  With newly diagnosed and untreated OR previously diagnosed, treated and&#xD;
                  uncontrolled Isolated Systolic Hypertension defined as:&#xD;
&#xD;
                    -  seated Systolic Blood Pressure (SBP) ≥ 160mmHg and &lt; 220 mmHg [160-220[&#xD;
&#xD;
                    -  AND seated Diastolic Blood Pressure (DBP)&lt; 90 mmHg&#xD;
&#xD;
          -  at Randomization&#xD;
&#xD;
               -  Having completed the 2 to 4-week wash-out/placebo run-in phase&#xD;
&#xD;
               -  Still eligible for Blood Pressure&#xD;
&#xD;
               -  seated SBP ≥ 160mmHg and &lt; 220 mmHg [160-220[&#xD;
&#xD;
               -  AND seated DBP &lt; 90 mmHg.&#xD;
&#xD;
        Exclusion Criteria (at Screening):&#xD;
&#xD;
          -  Participation in a clinical trial within the previous 3 months&#xD;
&#xD;
          -  Patients with a history of irbesartan, amlodipine, or hydrochlorothiazide sensitivity&#xD;
             defined as irbesartan, amlodipine, or hydrochlorothiazide discontinuation due to&#xD;
             medically significant adverse effects&#xD;
&#xD;
          -  Patients currently or previously treated with Angiotensin II Receptor Blocker&#xD;
             (irbesartan, losartan, candesartan, valsartan, telmisartan, etc.) or dihydropiridine&#xD;
             Calcium Channel Blocker (amlodipine, nicardipine, felodipine, nifedipine, etc.) AND&#xD;
             not responding despite maximum tolerated dose&#xD;
&#xD;
          -  Known or suspected secondary hypertension (e.g., coarctation of aorta, renovascular&#xD;
             stenosis, etc.)&#xD;
&#xD;
          -  Known single functional kidney&#xD;
&#xD;
          -  History of recent myocardial infarction, coronary artery bypass graft surgery or&#xD;
             percutaneous transluminal coronary angioplasty, or cerebrovascular accident (Transient&#xD;
             Ischaemic Attack, stroke) within the last 6 months of study entry&#xD;
&#xD;
          -  Patients with known gastrointestinal, renal, hepatic, endocrine, cardiovascular,&#xD;
             pulmonary, immunological or hematological disease which in the opinion of the&#xD;
             investigator is active or uncontrolled&#xD;
&#xD;
          -  Patients with significant renal (clearance of creatinine &lt; 30 mL/mn), hepatic or&#xD;
             cardiac insufficiency, or known valvular heart disease&#xD;
&#xD;
          -  Serum potassium &lt; 3.5 mmol/L (mEq/L) or &gt; 5.5 mmol/L (mEq/L)&#xD;
&#xD;
          -  Presence of clinically significant ventricular or supraventricular arrhythmias, or&#xD;
             second or third degree atrioventricular block, or QTc prolongation (Bazett &gt; 450&#xD;
             msec.) on the ECG&#xD;
&#xD;
          -  Pregnancy or lactation. Women of child bearing potential (not post-menopausal) should&#xD;
             be using a reliable contraceptive method&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascale BLONDIN, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Shangai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>China</country>
    <country>Indonesia</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>December 9, 2005</study_first_submitted>
  <study_first_submitted_qc>December 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2005</study_first_posted>
  <last_update_submitted>December 17, 2007</last_update_submitted>
  <last_update_submitted_qc>December 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

